NEWS
All News
Special Reports
CONFERENCES
Conference Coverage
Conference Listing
MEDIA
All Videos
Case-Based Peer Perspectives
Expert Perspective Virtual Tumor Board
Interviews
Investigator Perspectives
Medical World News
Podcasts
Precision Medicine
PUBLICATIONS
All Publications
Evolving Paradigms
Roundtable Meetings Spotlight
Targeted Therapies in Oncology
CME/CE
RESOURCES
Case-Based Roundtable Series
Clinical Trials
Partners
Precision Medicine Perspectives
Press Releases
Sponsored Content
Treatment Resources
SUBSCRIBE

logo
Featured Clinical Focus
AML
BTK Inhibitors: In-Focus
Biomarker-Driven Lung Cancer
Bone Marrow & SCT
CAR T-Cell Therapy
Chronic Lymphocytic Leukemia
EGFR-Positive Lung Cancer
Endometrial Cancer
Follicular Lymphoma
HCC
Lung Cancer
MPNs
Mantle Cell Lymphoma
Multiple Myeloma
Renal Cell Carcinoma
Small Cell Lung Cancer
Thyroid Cancers
Clinical Focus
Brain Cancer
Breast Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Gynecologic Cancers
Head & Neck Cancers
Hematology
Leukemias
Lung Cancer
Lymphomas
Melanoma
Sarcoma
Skin Cancers
Thyroid Cancers
Spotlight
Case Based Peer Perspectives
Case-Based Roundtable Series
Clinical Trials
Podcasts
Precision Medicine
Special Reports
All News
Special Reports
Conference Coverage
Conference Listing
All Videos
Case-Based Peer Perspectives
Expert Perspective Virtual Tumor Board
Interviews
Investigator Perspectives
Medical World News
Podcasts
Precision Medicine
All Publications
Evolving Paradigms
Roundtable Meetings Spotlight
Targeted Therapies in Oncology
CME/CE
Case-Based Roundtable Series
Clinical Trials
Partners
Precision Medicine Perspectives
Press Releases
Sponsored Content
Treatment Resources
SUBSCRIBE
Advertisement
BIOMARKER-DRIVEN LUNG CANCER
| BONE MARROW & STEM CELL TRANSPLANT
| GYNECOLOGIC CANCERS
| HEMATOLOGY
| LUNG CANCER
| SMALL CELL LUNG CANCER
| THYROID CANCERS
| BRAIN CANCER
| BREAST CANCER
| CAR T-CELL THERAPY
| ENDOMETRIAL CANCER
| GASTRIC CANCER
| GENITOURINARY CANCERS
| GENOMIC TESTING
| GI CANCERS
| HCC
| HEAD & NECK CANCERS
| IMMUNOTHERAPY
| LEUKEMIAS
| LYMPHOMAS
| MET-TARGETED THERAPY
| NTRK GENE FUSIONS
| SARCOMA
| SKIN CANCERS
View All >>
  • BIOMARKER-DRIVEN LUNG CANCER
  • BONE MARROW & STEM CELL TRANSPLANT
  • BRAIN CANCER
  • BREAST CANCER
  • CAR T-CELL THERAPY
  • ENDOMETRIAL CANCER
  • GASTRIC CANCER
  • GENITOURINARY CANCERS
  • GENOMIC TESTING
  • GI CANCERS
  • GYNECOLOGIC CANCERS
  • HCC
  • HEAD & NECK CANCERS
  • HEMATOLOGY
  • IMMUNOTHERAPY
  • LEUKEMIAS
  • LUNG CANCER
  • LYMPHOMAS
  • MET-TARGETED THERAPY
  • NTRK GENE FUSIONS
  • SARCOMA
  • SKIN CANCERS
  • SMALL CELL LUNG CANCER
  • THYROID CANCERS

SPOTLIGHT -

Case Based Peer Perspectives
| Case-Based Roundtable Series
| Clinical Trials
| Podcasts
| Precision Medicine
| Special Reports

A 73-Year-Old Woman With Differentiated Thyroid Cancer

home / case-based-peer-perspectives / a-73-year-old-woman-with-differentiated-thyroid-cancer

Andrew G. Gianoukakis, MD, of Harbor-UCLA Medical Center, describes the rationale for treating a patient with RAI-refractory differentiated thyroid cancer with systemic therapy.


Case Impressions: A 73-Year-Old Woman With DTC

EP. 1: Case Impressions: A 73-Year-Old Woman With DTC

Andrew G. Gianoukakis, MD
September 25th 2020

Watch


Recommendations for Treating Patients With DTC

EP. 2: Recommendations for Treating Patients With DTC

Andrew G. Gianoukakis, MD
September 25th 2020

Watch


Systemic Therapy for RAI-Refractory DTC

EP. 3: Systemic Therapy for RAI-Refractory DTC

Andrew G. Gianoukakis, MD
September 25th 2020

Watch


Lenvatinib Data for RAI-Refractory DTC

EP. 4: Lenvatinib Data for RAI-Refractory DTC

Andrew G. Gianoukakis, MD
September 25th 2020

Watch


Real-World Insight: Lenvatinib for RAI-Refractory DTC

EP. 5: Real-World Insight: Lenvatinib for RAI-Refractory DTC

Andrew G. Gianoukakis, MD
September 25th 2020

Watch


Progress in Treating RAI-Refractory DTC

EP. 6: Progress in Treating RAI-Refractory DTC

Andrew G. Gianoukakis, MD
September 25th 2020

Watch


Higher Dose Cabozantinib Demonstrates Superior Efficacy Over Lower Dose in MTC

EP. 7: Higher Dose Cabozantinib Demonstrates Superior Efficacy Over Lower Dose in MTC

Sara Karlovitch
October 7th 2021

The 140 mg dosage was associated with a higher rate of adverse events and dose reductions.

Read More

About Us
Advertise
Contact Us
CureToday.com
CancerNetwork.com
OncLive.com
OncNursingNews.com
Do Not Sell My Information
Privacy
Terms & Conditions
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.